ç±³åœæ¿åºãä»ãè³éãæäŸããŠãã3ã€ã®æªæ¥åãã€ãªãã¯ãããžãŒã»ããã°ã©ã
FUTUREÂ FRONTIERS
10æ31æ¥ïœ2018
Kira Peikoff
å èšäºã¯ãã¡ãã
ç¹éèšäºãã€ãªãã¯ãããžãŒ
ãã€ãªã¡ãã£ã«ã«ãšã³ãžãã¢ã®ã±ãã³ã»ã¶ãªã¯ãè
ãšèžã«ã»ã³ãµãŒãè£
çãããããã®çµç¹å
ã®é
žçŽ æ¿åºŠããªã¢ã«ã¿ã€ã ã§ç£èŠããŠããã
å æãåœé²ç·çã®ç ç©¶éšéã§ããDARPAãç¥ãäŒè°ã§ãFBIç¹å¥ææ»å®ã®ãšãã¯ãŒãã»ãŠãŒãã"21äžçŽã¯çåœç§åŠã®é©åœã«ãªã "ãšå®£èšããã®ã§ãã
ãã€ãªã¡ãã£ã«ã«ãšã³ãžãã¢ã®ã±ãã³ã»ã¶ãªã¯ãè
ãšèžã«é
žçŽ æ¿åºŠããªã¢ã«ã¿ã€ã ã§ç£èŠããã»ã³ãµãŒãè£
çããŠããã
å®éã4幎åã«ã¯ãã€ãªãã¯ãããžãŒãæšé²ããããã ãã®æ°ãããªãã£ã¹ãèšçœ®ãããããã®äž»ãªç®çã¯ããã€ãªãããšæŠããç±³è»ãä¿è·ããæŠéå¡ã®å³å¿æ§ãä¿é²ããããšã§ããããããããã®ç ç©¶ã¯äžè¬åžæ°ã®å¥åº·ç®¡çã®æ¹åã«ãåŒãç¶ãããå¯èœæ§ãããã
幎éäºç®çŽ30åãã«ã®DARPAã®è·å¡ã¯ãçŽ250ã®ç ç©¶éçºããã°ã©ã ãç£ç£ããäŒæ¥ã倧åŠãæ¿åºã®ç ç©¶æããã®è«è² æ¥è ãšååããŠãæ°ããæè¡ãå®çŸããããã«åããŠããŸãã
çŸåšé²è¡äžã®3ã€ã®ããã°ã©ã ãã玹ä»ããŸãã
1ïŒé žçŽ ãä¹³é žãã°ã«ã³ãŒã¹ã¬ãã«ããªã¢ã«ã¿ã€ã ã§æž¬å®ããåã蟌ã¿åã»ã³ãµãŒ
ãã€ãªã¡ãã£ã«ã«ãšã³ãžãã¢ã®ã±ãã³ã»ã¶ãªã¯ãè ãšèžã«ã»ã³ãµãŒãè£ çãããããã®çµç¹ã®é žçŽ æ¿åºŠããªã¢ã«ã¿ã€ã ã§ã¢ãã¿ãŒããŠããŸããDARPAã®ãIn Vivo Nanoplatformsãããã°ã©ã ã«ããè³éæäŸãåããŠãåœŒã¯æãããæè»ãªãã€ããã²ã«ãéçºããããã®ãã€ããã²ã«ã¯ç®èã®ããäžã«æ³šå ¥ããŠã¢ãã¿ãªã³ã°ãè¡ããã¹ããŒããã©ã³ã®ã¢ããªãšåæããŠãŠãŒã¶ãŒã«å¥åº·ã«é¢ããæŽå¯ãå³åº§ã«äžããã
Zhaoæ°ã«ãããšããã®ã°ã«ã³ãŒã¹ã»ã³ãµãŒã¯çŸåšãšãŒãããã§ç³å°¿ç æ£è ã®ã¢ãã¿ãªã³ã°ãç®çãšããåã®äººäœå®éšãè¡ãããŠããããã©ã³ãã£ã¢ã¯ãçããã®ãé£ã¹ãŠã°ã«ã³ãŒã¹å€ãæ¥äžæãããã¢ãã¿ãŒã«ãã®å€åãç»é²ããããä¿ãã
ããããããŸãããã°ãFDAã®æ¿èªãåŸãŠãæ¶è²»è ã¯ã»ã³ãµãŒãäœã®è¯ã«åã蟌ãã§ãã°ã«ã³ãŒã¹ãé žçŽ ãä¹³é žã®ã¬ãã«ã枬å®ã§ããããã«ãªãããšZhaoã¯èšãã
ç¹ã«ä¹³é žã¯ãå€å·ãæè¡çãææçãªã©ã®çºçã«ãã¡æ©ãåå¿ããååã§ãããããDARPAãé¢å¿ãå¯ããŠããã®ã§ãã
"ã»ã³ãµãŒã¯ããããã®ïŒäœå ååŠæ°å€ã®ïŒäžæãæ€åºããå±éºãªç æ°ã®çºçãé²ãããã«ãŠãŒã¶ãŒã«èŠåãçºããããšãã§ããå¯èœæ§ããããŸãã"
2) ãã³ãããã¯æã®ã»ãŒç¬æã®ã¯ã¯ãã³é²åŸ¡
åŸæ¥ã®ã¯ã¯ãã³ã¯ãéçºãŸã§ã«æ°ã¶æããæ°å¹ŽããããŠæ¥çš®ããŠãã广ãåºããŸã§ã«æ°é±éãããããšããããŸãããããããæªç¥ã®ãŠã€ã«ã¹ãåºçŸããå Žåãç¡é§ã«ããŠããæã¯ãªãã®ã§ãã
P3ããšåŒã°ãããã®ããã°ã©ã ã§ã¯ããã³ãããã¯ãæªç¶ã«é²ãããã«ãããéå¿çãªã¢ãããŒããæ³å®ããŠããŸãã
ãã®ããã°ã©ã ã»ãããŒãžã£ãŒã®ãã·ã¥ãŒã»ãããããŒã³å€§äœã¯ããæã ã¯ãæ²»çè¬ãçç£ããããã®ãã€ãªãªã¢ã¯ã¿ãŒãšããŠäººäœãå©çšãããšããããããŸã§ãšã¯éã£ãæ¹æ³ã§ãã»ãŒç¬æã«é²åŸ¡ãäžããããšèããŠããŸãããšè¿°ã¹ãŠããã
ã§ã¯ãã©ã®ããã«äœ¿ãã®ã ãããïŒ
ãã³ãããã¯ã«å¯Ÿæããããã«ã¯ã60æ¥éã«2äžååã®ã¯ã¯ãã³ãå¿
èŠã§ãã
ããææçã«å¯Ÿããæäœãæã£ãŠããã°ããã®ææçããå®ãããããšã«ãªãããã®ã¢ã€ãã¢ã¯ãç¹å®ã®ç
åäœã«å¯Ÿããæäœã®éºäŒåã³ãŒããçºèŠãããã®DNAãšRNAã®æçã補é ãããã®ã³ãŒãã人ã®è
ã«æ³šå°ããããšã§ãçè现èãå¿
èŠãªæäœãäœãå§ããããã«ãããã®ã§ãã
ãããããŒã³æ°ã¯ããé©ãã¹ãããšã¯ãå°ãªããšãåç©ã¢ãã«ã§ã¯ããããå®éã«æ©èœããããšã§ãããšèšãã"ããŠã¹ã®çèã¯ãããŠã¹ãä¿è·ããã®ã«ååãªéã®æäœãäœããŸããã"
次ã®ã¹ãããã¯ããã®ã¢ãããŒããããã§ãã¹ãããããšã§ããã®ããã°ã©ã ã¯ãä»åŸ2幎éãããŠãããè¡ãäºå®ã§ãã
ãããããããããŒã³æ°ã«ããã°ãé£ããã®ã¯ãå®ã¯ãéåžžã«åŒ·åãªæäœã®éºäŒåã³ãŒããçºèŠããããšã§ã¯ãªãã®ã ããã§ããå®éãç ç©¶è ãã¡ã¯ãã§ã«2é±éãã4é±éã®æéã§ãããå®çŸããŠããã
ãé£ããã®ã¯ãäžåºŠæäœãäœããšã倧æã®è£œè¬äŒç€Ÿã¯2幎åŸã«ã¯100ã200ååäœãããšèšãããšã§ãã2äžåæäžã§ããããã«ãªããŸã§ã«4幎ãã ããããããããã¡ãªãã ããšãããããŒã³ã¯èšãã
ãã³ãããã¯ã«å¯Ÿæããããã«ã¯ã60æ¥éã§2äžååã®ã¯ã¯ãã³ãå¿ èŠã«ãªãã
"è¬ãäœãã«ã¯10åãã«ã10幎ããã "ãšããèããæ ¹æ¬ããå€ããªããã°ãªããªãããšç· ãããã£ãã"æ ¹æ¬çã«éãããšããããã  "ãšã
3ïŒãšããžã§ããã£ã¯ã¹ã«ããç åäœæé²ã®è¿ éãªèšºæ
ããªããè¬ã®ç æ°ã«ããã£ããšããŸãããŠã€ã«ã¹ããã¯ããªã¢ããããã¯æ¥µç«¯ãªå€§çœå®³ã§ã¯å€§éç Žå£å µåšã«ããçç©åŠç補å€ãåå ã§ããå¯èœæ§ãããã
ãããããªããã©ã®ç
åäœã«ãã€ããããããã30å以å
ã«ç¹å®ã§ããæºåž¯æ©åšããã£ããã©ãã ããïŒæŠå Žã«ããå
µå£«ã ãã§ãªããæ²»çãåããããšããäžè¬åžæ°ã«ãšã£ãŠããããã¯é©ãã¹ãããšã ããã
ããã¯ãDARPAïŒç±³åœåœé²é«çç ç©¶èšç»å±ïŒã®ãEpigenetic Characterization and ObservationãïŒECHOïŒãšåŒã°ããããã°ã©ã ã®é«ãç®æšã§ããã
ãã®èšç»ã®æåã¯ããšãã²ãã ãšåŒã°ããçç©åŠççŸè±¡ã«äŸåããŠããŸããDNAã¯æ¯èŒçäžå€ã§ãããç°å¢ã¯DNAã®çºçŸãå€åãããæ°ç§ããæ°åã®ãã¡ã«ãã®çè·¡ãæ®ãããã®çè·¡ã¯äœå幎ãç¶ãããšããããŸããåãDNAãæã€äžåµæ§åçå ããå¥åº·ç¶æ ãæ°è³ªãå€èŠã«éããããã®ã¯ããšãã²ãã ã®ãããã§ãã
ãã®3å¹ã®ããŠã¹ã¯éºäŒåŠçã«åäžã§ããããããããšããžã§ããã£ãã¯ãªéãã«ããã芳å¯ãããç¹æ§ã¯å€§ããç°ãªãã
(© 1994 Nature Publishing Group Duhl, D. et al. Neomorphic agouti mutations in obese yellow mice.ãè¥æºã€ãšããŒããŠã¹ã®æ°åã¢ã°ãŒãå€ç°ã. Nature Genetics 8, 60.)
ãšããžã§ããã£ãã¯ããŒã¯ãèªã¿åãã°ãçè«çã«ã¯ãäœå ã®ç°å¢æŽé²ã®å±¥æŽãã¿ã€ã ã¹ã¿ã³ãã§è¡šç€ºããããšãã§ããã
ECHOããã°ã©ã ã®ç ç©¶è ãã¡ã¯ãæé²äºè±¡ã®ã·ã°ããã£ãŒã®ããŒã¿ããŒã¹ãäœæããæ³å®ããŠããè£ çœ®ãã誰ãã®ãšãã²ãã ãçŽ æ©ãã¹ãã£ã³ããããŒã¿ããŒã¹ãåç §ããŠèšºæãéžå¥ã§ããããã«ããããšãèšç»ããŠããŸãã
ECHOããã°ã©ã ãããŒãžã£ãŒãæè¡çã«æ¯æŽããŠããå¥çŽç§åŠè ã®Thomas Thomouã¯ãã1ã€é£ããã®ã¯ããã®çµæã«ãã©ã®è¢«æã§ãã£ããã®ãµã€ã³ã«å ããŠããã®è¢«æããã€èµ·ãã£ããã瀺ãã¿ã€ã ã¹ã¿ã³ããä»ããããšã§ãããšèšãã
ãã®ä»ã®çåã¯ãä»ã®ãšãããŸã å®ã«æµ®ãããŸãŸã§ããããã¹ãŠã®äººéããåãæé²äºè±¡ã«å¯ŸããŠåããšããžã§ããã£ãã¯ãªåå¿ã瀺ãã®ã ãããïŒãŠã€ã«ã¹ãšçްèã«ãã被æãåºå¥ããããšã¯å¯èœãªã®ãïŒãšãã²ãã 修食ã®ã·ã°ããã£ãŒã«ãæé²éãæé²æéã¯åœ±é¿ããã®ãïŒ
ãã®ããã°ã©ã ã¯2019幎1æã«ããã¯ãªãããéäžã§éçºã®äžå®ã®ãã€ã«ã¹ããŒã³ã«å°éããéãã4幎éç¶ç¶ããäºå®ã§ããæãŸãããããã¿ã€ãã¯ãèšç·ŽãåããŠããªã人ã§ããç¶¿æ£ãæãåºããŠæäœã§ãããããªã·ã³ãã«ãªè£ 眮ãšãªãã
ããã¢ãŠå士ã¯ããææçãçºçãããšããå
¬è¡è¡çã®å®å
šã«å€§ããªåœ±é¿ãåãŒãå¯èœæ§ã®ããåé¡ã«å¯ŸããŠãéåžžã«è¿
éãªçããäžããŠããããè¿
éã«å±éã§ããæ©æ¢°ãããã°ãçŸå Žã«ããå
šå¡ãããã«å©ããã§ãããããšè¿°ã¹ãŠããŸãã